Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna (NASDAQ:MRNA) on Thursday, setting a price target of $85, which is approximately 79.45% below the present share price of $413.72.
Foroohar expects Moderna to post earnings per share (EPS) of $3.05 for the third quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Hold rating of shares in Moderna, with an average price target of $305.
The analysts price targets range from a high of $463 to a low of $85.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.94 billion and a net profit of $1.27 billion. The company's market cap is $166.12 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.8% and a 37.50% success rate.
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.